Intellia Therapeutics (NTLA) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Stifel Reiterates Buy Rating on Intellia Therapeutics (NTLA)
November 7, 2024 10:43 AM ESTStifel analyst Dae Gon Ha reiterated a Buy rating and $54.00 price target on Intellia Therapeutics (NASDAQ: NTLA).
The analyst comments "NTLA has one of the most expansive and diversified pipelines within the CRISPR/Cas gene editing field, and with 3 Ph.3 studies... More
